 ST.GALLEN, Switzerland STAMFORD, Conn.--BUSINESS WIRE--Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. Nasdaq: CARA today announced that the U.S. Food and Drug Administration FDA has accepted and granted Priority Review for the New Drug Application NDA for KORSUVATM difelikefalin solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVATM is 23 August 2021. The FDA stated that currently it is no 